Biosig Technologies Q4 2025 Earnings Report

Biosig Technologies EPS Results

• Actual EPS: -$8.23
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Biosig Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Biosig Technologies Announcement Details

• Quarter: Q4 2025
• Date: 3/31/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Biosig Technologies (NASDAQ:STEX) (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion. The technology is intended to integrate with existing electrophysiology lab equipment and workflows, supporting procedures such as ablations used to treat atrial fibrillation and other arrhythmias. By enhancing signal fidelity, the company aims to support procedural efficiency and clinical decision-making for electrophysiologists and hospital electrophysiology labs.

Biosig positions its product development around clinical validation and regulatory pathways common to medical device commercialization, and it targets adoption by hospitals, specialty clinics and physician groups that perform invasive cardiac electrophysiology procedures. The company pursues clinical studies and collaborations to demonstrate the clinical utility of its technology and to support broader commercialization within the medical community.